{
    "clinical_study": {
        "@rank": "132905", 
        "arm_group": {
            "arm_group_label": "irinotecan Hydrochloride", 
            "arm_group_type": "Experimental", 
            "description": "irinotecan Hydrochloride, at least 3cycels or till Progressive Disease or death"
        }, 
        "brief_summary": {
            "textblock": "A phaseII trial of second-line irinotecan  Hydrochloride  in Metastatic Breast Cancer.\n      Evaluate the effect and safety of  irinotecan  Hydrochloride  in Metastatic breast cancer\n      patients whose disease recurrent after using anthracycline or taxane drugs. The endpoint is\n      Disease Control Rate and Progression free survival. The second endpoint is Adverse Events\n      and Sever Adverse Events.The duration of irinotecan is at least 3 cycles(61 days), till dead\n      or ."
        }, 
        "brief_title": "A Phase II Study of Second-line Irinotecan Hydrochloride in Metastatic Breast Cancer.", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Stage IIIB, IV, Recurrent, and Metastatic Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "The endpoint is Disease Control Rate  and Progression free survival. The second endpoint is\n      Adverse Events and Sever Adverse Events.The duration of Iriontecan is at least 3 cycles(61\n      days), till dead or Progressive Disease."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Mestatic breast cancer patients whose disease recurrent after using anthracycline or\n             taxane drugs\n\n        Exclusion Criteria:\n\n          -  Heart Disease.etc"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "35", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02030678", 
            "org_study_id": "STao"
        }, 
        "intervention": {
            "arm_group_label": "irinotecan Hydrochloride", 
            "description": "irinotecan  Hydrochloride, 350mg/m2,at least 3cycles,21days/cycle.", 
            "intervention_name": "irinotecan  Hydrochloride", 
            "intervention_type": "Drug", 
            "other_name": "Kaiputuo"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Irinotecan", 
                "Camptothecin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 7, 2014", 
        "location": {
            "contact": {
                "email": "jianong@126.com", 
                "last_name": "Tao Sun, Doctor"
            }, 
            "facility": {
                "address": {
                    "city": "Shenyang", 
                    "country": "China", 
                    "state": "Liaoning", 
                    "zip": "110000"
                }, 
                "name": "SunTao"
            }, 
            "investigator": {
                "last_name": "Tao Sun, Doctor", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Study of Second-line Irinotecan Hydrochloride in Metastatic Breast Cancer", 
        "overall_contact": {
            "email": "jianong@126.com", 
            "last_name": "Tao Sun, Doctor"
        }, 
        "overall_official": {
            "affiliation": "Liaoning Tumor Hospital & Institute", 
            "last_name": "Tao Sun, Doctor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Disease Control Rate:Completely Response+Partial Response+Stable Disease", 
            "measure": "Disease Control Rate", 
            "safety_issue": "Yes", 
            "time_frame": "3cycles (21days/cycle)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02030678"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Liaoning Tumor Hospital & Institute", 
            "investigator_full_name": "Sun Tao", 
            "investigator_title": "Director of Oncology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Liaoning Tumor Hospital & Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Liaoning Tumor Hospital & Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}